By now it’s well-known that the postgrant proceedings implemented with the America Invents Act have had a huge impact on the patent practices of companies in the technology and electronics fields. But the proceedings also have significantly altered the patent strategies used by in-house lawyers in the pharmaceutical and biotechnology sectors, according to a new survey.
The 2015 edition of Consero Group’s “IP Pharmaceuticals & Biotechnology Data Survey,” which is being released today, found that 78 percent of chief intellectual property officers said the AIA has changed their approach to the patent process. In 2013, only 59 percent said this was true.
